Xigen SA - Product Pipeline Review - H2 2011
Global Markets Direct
November 28, 2011 31 Pages - SKU: GMD6692246
|
|
Xigen SA - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Xigen SA - Product Pipeline Review - H2 2011” provides data on the Xigen SA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xigen SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Xigen SA and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope - Xigen SA - Brief Xigen SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xigen SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Xigen SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Xigen SA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy - Evaluate Xigen SA’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Xigen SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Xigen SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Xigen SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Xigen SA and identify potential opportunities in those areas.
|
- Xigen SA Snapshot
- Xigen SA Overview
- Key Information
- Key Facts
- Xigen SA - Research and Development Overview
- Key Therapeutic Areas
- Xigen SA - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Xigen SA - Pipeline Products Glance
- Xigen SA Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Xigen SA-Early Stage Pipeline Products
- Discovery Products/Combination Treatment Modalities
- Xigen SA - Drug Profiles
- XG-102
- Product Description
- Mechanism of Action
- R&D Progress
- XG-2xx
- Product Description
- Mechanism of Action
- R&D Progress
- XG-3xx1
- Product Description
- Mechanism of Action
- R&D Progress
- XG-4xx
- Product Description
- Mechanism of Action
- R&D Progress
- XG-5xx
- Product Description
- Mechanism of Action
- R&D Progress
- Xigen SA - Pipeline Analysis
- Xigen SA - Pipeline Products by Therapeutic Class
- Xigen SA - Pipeline Products By Target
- Xigen SA - Pipeline Products by Route of Administration
- Xigen SA - Pipeline Products by Molecule Type
- Xigen SA - Locations And Subsidiaries
- Head Office
- Financial Deals Landscape
- Xigen SA, Deals Summary
- Xigen SA, Pharmaceuticals & Healthcare, Deal Details
- Venture Financing
- Xigen Raises $20 Million In Series B Financing
- Xigen Secures $21 Million In Series A Financing
- Xigen Completes Venture Financing Round
- Xigen Secures Venture Financing
- Licensing Agreements
- Auris Medical Enters Into Licensing Agreement With Xigen
- Acquisition
- Venture Incubator Completes Sale Of Its Stake In Xigen
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Xigen SA - Pipeline by Therapy Area and Indication, H2 2011
- Xigen SA - Pipeline by Stage of Development, H2 2011
- Xigen SA - Monotherapy Products in Pipeline, H2 2011
- Xigen SA - Phase II, H2 2011
- Xigen SA - Pipeline By Therapeutic Class, H2 2011
- Xigen SA - Pipeline By Target, H2 2011
- Xigen SA - Pipeline By Route of Administration, H2 2011
- Xigen SA - Pipeline By Molecule Type, H2 2011
- Xigen SA, Deals Summary
- Xigen Raises $20 Million In Series B Financing
- Xigen Secures $21 Million In Series A Financing
- Xigen Completes Venture Financing Round
- Xigen Secures Venture Financing
- Auris Medical Enters Into Licensing Agreement With Xigen
- Venture Incubator Completes Sale Of Its Stake In Xigen
- List of Figures
- Xigen SA - Pipeline by Therapy Area and Indication, H2 2011
- Xigen SA - Pipeline by Stage of Development, H2 2011
- Xigen SA - Monotherapy Products in Pipeline, H2 2011
- Xigen SA - Pipeline By Therapeutic Class, H2 2011
- Xigen SA - Pipeline By Target, H2 2011
- Xigen SA - Pipeline By Molecule Type, H2 2011
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
